You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

 

Online download statistics by month:

Online download statistics by month: June 2020 to July 2025

AbstractFullPdf
Jun 2020301301167
Jul 202017517539
Aug 2020636337
Sep 2020616125
Oct 2020636321
Nov 2020666922
Dec 2020666621
Jan 2021727216
Feb 2021868634
Mar 2021747426
Apr 202110310323
May 2021707015
Jun 2021494837
Jul 2021535320
Aug 2021424225
Sep 2021444428
Oct 2021626238
Nov 2021595946
Dec 2021626440
Jan 2022424522
Feb 2022606123
Mar 2022616338
Apr 2022929537
May 2022747631
Jun 2022808333
Jul 2022586019
Aug 2022868639
Sep 2022636427
Oct 2022606233
Nov 2022727430
Dec 2022595912
Jan 2023454516
Feb 2023737318
Mar 2023454611
Apr 2023838316
May 2023363619
Jun 2023404017
Jul 2023424316
Aug 2023454817
Sep 202341418
Oct 2023464610
Nov 2023707027
Dec 2023363722
Jan 2024636415
Feb 2024515227
Mar 2024686886
Apr 202412512744
May 2024414222
Jun 2024505333
Jul 2024596432
Aug 2024414122
Sep 2024424628
Oct 2024555528
Nov 2024616440
Dec 2024555523
Jan 2025434431
Feb 2025454523
Mar 2025555538
Apr 2025676734
May 2025464724
Jun 2025363621
Jul 2025110
Total398440371792